Study targeting telomeres in progeria models highlights a potential breakthrough in cellular aging research.
Telomir Pharmaceuticals, a pharmaceutical company specializing in age-reversal science, has announced findings from a preclinical study that demonstrate the potential of Telomir-1 to restore lifespan and normalize accelerated aging in models of progeria, a rare genetic condition. Conducted in collaboration with Nagi Bioscience, the research used C elegans nematode models to explore the therapeutic promise of Telomir-1 in addressing the cellular mechanisms of aging.
Longevity.Technology: Telomeres, often likened to protective caps at the ends of shoelaces, sit at the end of chromosomes and play a critical role in cellular aging by safeguarding DNA from damage. However, as cells divide, telomeres shorten; this process is linked to the Hayflick limit – the maximum number of times a cell can divide before becoming senescent. Accelerated telomere shortening, seen in conditions such as progeria, leads to widespread cellular dysfunction and premature aging and intervening in this process could have profound implications for extending both lifespan and healthspan, making telomere biology a focal point of geroscience research.
While progeria, also known as Hutchinson-Gilford Progeria Syndrome, is not a common disorder, affecting fewer than 400 children worldwide, it is a devastating one. The condition is characterized by the accumulation of progerin, a defective protein that disrupts the integrity of the cell nucleus and accelerates telomere degradation. This molecular damage manifests as rapid aging, with patients often succumbing to cardiovascular complications in their early teens or twenties. Progeria research holds profound significance beyond the rare disorder itself, as it provides unique insights into the mechanisms of cellular aging, such as telomere attrition, DNA damage and nuclear instability; these findings can inform broader longevity research, potentially uncovering therapeutic strategies to mitigate age-related diseases and promote healthier aging in the general population.
Telomir-1: A multifaceted therapeutic approach
Telomir-1, a novel small molecule developed by Telomir, is designed to address the underlying causes of cellular damage and dysfunction by targeting excess metal activity, a factor implicated in oxidative stress, ferroptosis (iron-dependent cell death) and inflammation – all of which accelerate telomere shortening and aging.
Laurent Mouchiroud, PhD, cofounder and CSO of Nagi Bioscience claimed that analysis of the trial results show that Telomir-1 not only “restores lifespan but also effectively counters the decline seen in untreated populations”.
“These findings highlight Telomir-1’s potential to redefine how we approach age-related conditions by addressing their underlying cellular mechanisms,” he added.
The latest findings are based on two studies conducted on populations of 80 to 150 C elegans nematodes in each group. Using detailed Kaplan-Meier survival analysis, the results demonstrated that progeria-affected nematodes, which typically have a lifespan of 9–10 days compared with the 12–15 days observed in normal nematodes, experienced a significant lifespan extension upon treatment with Telomir-1. The therapy added an additional 2–5 days of survival, effectively closing the gap between the lifespans of progeria and normal nematodes. Importantly, there was no statistical difference in lifespan between Telomir-1-treated nematodes and their healthy counterparts, demonstrating the molecule’s ability to normalize lifespan disrupted by progeria mutations.
This normalization effect highlights the potential of Telomir-1 to address cellular dysfunction at its core, particularly in conditions characterized by accelerated telomere shortening. By restoring lifespan in progeria models to levels indistinguishable from normal populations, Telomir-1 offers compelling evidence for its therapeutic promise in tackling the underlying mechanisms of accelerated aging, albeit in C elegans at this stage.
Erez Aminov, Chairman and CEO of Telomir Pharmaceuticals, told Longevity.Technology that follow-up studies are on the cards and the company is “committed to publishing a scientific paper to share these findings in greater detail.”
Mechanism of action
A key component of Telomir-1’s therapeutic strategy is its ability to regulate essential metal ions. Excess iron, for instance, is a major contributor to oxidative stress and mitochondrial dysfunction; it has been linked to neurodegeneration, insulin resistance and bone disorders. Similarly, copper imbalances can impair metabolic function and exacerbate conditions such as Wilson’s disease. By modulating these metal activities, Telomir-1 aims to preserve cellular health and slow the progression of age-related conditions.
“These results represent a significant milestone in our mission to develop therapies that address the root causes of diseases,” said Dr Itzchak Angel, Chief Scientific Advisor at Telomir. “Telomir-1’s ability to significantly restore lifespan and normalize accelerated aging in progeria models demonstrates its promise as a transformative therapeutic option.”
Implications for broader applications
Telomir says the study’s findings align with other preclinical research that underscores Telomir-1’s potential in addressing a wide range of conditions, including type 2 diabetes, where the molecule has shown promise in reversing insulin resistance and achieving glycemic control in preclinical models, and general aging, where Telomir-1 appears to be able to reverse some biological markers of aging, meaning it may well have application in extending both lifespan and healthspan.
“Our research continues to validate Telomir-1’s ability to tackle aging at its core,” said Aminov. “By focusing on critical cellular processes, Telomir-1 offers a novel pathway to addressing conditions like progeria while also exploring its broader potential in other age-related diseases.”
Longevity.Technology asked Aminov about how Telomir plans to translate Telomir-1’s preclinical success in progeria models to human trials.
He told us that progeria studies will depend on several mechanistic factors that remain to be fully determined.
“These factors will ultimately shape our clinical targets and endpoints,” he said. “Addressing these challenges will require robust preclinical validation, a clear understanding of disease biology, and collaboration with regulatory bodies to establish appropriate trial designs.”
When it comes to prioritizing Telomir-1’s development pipeline for conditions like type 2 diabetes while still maintaining a focus on age-reversal application, Aminov told us that prioritization will be guided by unmet medical needs, efficacy data from ongoing studies and market factors.
“Throughout its development, age-reversal will remain a central focus, and we will adapt to regulatory requirements to ensure this remains a key part of Telomir-1’s therapeutic potential,” he explained.
Not the end of the line
Building on these results, Telomir Pharmaceuticals is preparing to initiate in vitro studies using human progeria cell lines in order to further validate Telomir-1’s efficacy in restoring cellular health and mitigating accelerated aging. The long-term goal is to develop and gain regulatory approval for Telomir-1, proposed to be dosed orally. However, Telomir-1 remains in the preclinical stage and has not yet been tested in humans.
As the company advances its research, regulatory approval and human trials will be critical milestones in determining the molecule’s viability as a therapeutic option, but if Telomir can leverage its insights into telomere biology to create therapies that address the root causes of degenerative diseases, then this could mark a significant breakthrough in the field of longevity science and age-related disease management.
